{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069159","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.826231+00:00","generated_at":"2026-05-22T01:07:03.024168+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FibroGen Q1 net loss narrows to $16.8M; China sale consideration raised to ~$185M","bullets":["Total revenue from continuing ops fell to $2.7M from $25.4M YoY; net loss improved to $16.8M ($0.16/sh) from $49.0M.","Sale of FibroGen China to AstraZeneca now expected total consideration ~$185M (enterprise $85M + net cash ~$100M); close in 3Q-2025.","Upon China sale close, cash runway extended into 2H 2027; Morgan Stanley term loan to be repaid.","Phase 2 monotherapy trial of FG-3246 (CD46 ADC) in mCRPC expected to start 3Q-2025; topline combo data from UCSF study due 4Q-2025.","Filed Type-C meeting request with FDA for roxadustat in LR-MDS anemia; feedback expected in 3Q-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069159","json":"https://secwatch.observer/filing/0000950170-25-069159.json","markdown":"https://secwatch.observer/filing/0000950170-25-069159.md","text":"https://secwatch.observer/filing/0000950170-25-069159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/0000950170-25-069159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:07:03.024168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}